Abeona Therapeutics (ABEO) IND App for ABO-101 Phase 1/2 Allowed by U.S. FDA
Tweet Send to a Friend
Abeona Therapeutics Inc. (NASDAQ: ABEO) ABO-101 is Abeona's second AAV gene therapy to commence clinical trials in a rare CNS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
